Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1.

Division of Nephrology, Department of Internal Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham St, Little Rock, AR 72205, USA.
Arteriosclerosis Thrombosis and Vascular Biology (Impact Factor: 6.34). 05/2007; 27(4):826-32. DOI: 10.1161/01.ATV.0000258795.75121.8a
Source: PubMed

ABSTRACT Carbamylated low-density lipoprotein (LDL), the most abundant modified LDL isoform in human blood, has been recently implicated in causing the atherosclerosis-prone injuries to endothelial cells in vitro and atherosclerosis in humans. This study was aimed at testing the hypothesis that carbamylated LDL acts via inducing monocyte adhesion to endothelial cells and determining the adhesion molecules responsible for the recruitment of monocytes.
Exposure of human coronary artery endothelial cells with carbamylated LDL but not native LDL caused U937 monocyte adhesion and the induction of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 adhesion molecules as measured by cell enzyme-linked immunosorbent assay. Silencing of intercellular adhesion molecule-1 by siRNA or its inhibition using neutralizing antibody resulted in decreased monocyte adhesion to the endothelial cells. Similar silencing or neutralizing of vascular cell adhesion molecule-1 alone did not have an effect but was shown to contribute to intercellular adhesion molecule-1 when tested simultaneously.
Taken together, these data provide evidence that intercellular adhesion molecule-1 in cooperation with vascular cell adhesion molecule-1 are essential for monocyte adhesion by carbamylated low-density lipoprotein-activated human vascular endothelial cells in vitro.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study we examined whether low-density lipoprotein (LDL) receptor family members represent a link between blood flow characteristics and modified low-density lipoproteins involved in endothelial injury, a pivotal factor in atherogenesis. We demonstrated the expression of pro-atherogenic LDL receptor relative (LR11) for the first time in human coronary artery endothelial cells (HCAEC) in vitro and in vivo. Next, LR11 expression and regulation were explored in HCAEC cultured conventionally or on the inner surface of hollow fiber capillaries under exposure to shear stress for 10 days in the presence or absence of LDL. There was no LR11 expression under static conditions. When exposed to chronic low shear stress (2.5 dynes/cm²) transmembrane and soluble endothelial-LR11 were detected in high levels irrespective of the type of LDL added (carbamylated or native). In contrast, chronic high shear stress (25 dynes/cm²) inhibited the LR11-inducing effect of LDL such that transmembrane and soluble LR11 expression became non-detectable with native LDL. Carbamylated LDL significantly counteracted this atheroprotective effect of high shear stress as shown by lower, yet sustained expression of soluble and transmembrane LR11. Oxidised LDL showed similar effects compared to carbamylated LDL but caused significantly lower LR11 expression under chronic high shear stress. Medium from HCAEC under LR11-inducing conditions enhanced vascular smooth muscle cell migration, which was abrogated by the anti-LR11 antibody. Expression of LR11 depended entirely on p38MAPK phosphorylation. We conclude that coronary endothelial LR11 expression modulated by LDL and chronic shear stress contributes to atherogenesis. LR11 and p38MAPK are potential targets for prevention of atherosclerosis.
    Thrombosis and Haemostasis 11/2013; 111(3). · 5.76 Impact Factor
  • Source
    Atherogenesis, 01/2012; , ISBN: 978-953-307-992-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: LDL is subjected to proatherogenic modifications in the circulation. A novel uremia-independent mechanism of carbamylation of lipoproteins mediated by myeloperoxidase (MPO) has recently been reported. We have investigated whether carbamylation of LDL was increased in type 2 diabetic patients without renal impairment and the role of MPO. Methods: Carbamylated LDL (cLDL) and MPO was measured by ELISA in a cross sectional study of 198 patients and 174 non-diabetic controls. The impact of lowering MPO on plasma cLDL was determined by assaying cLDL and MPO in archived samples from a previous randomized, open-label, parallel group study comparing rosiglitazone (n=20) and sulphonylurea (n=24). Results: Both plasma cLDL (p<0.05) and MPO levels (p<0.01) were higher in type 2 diabetic patients than controls in the cross sectional study. Plasma cLDL correlated with MPO (r=0.42, p<0.01) in subjects with diabetes, and plasma MPO was an independent determinant of plasma cLDL even after adjusting for age, gender, body mass index, apo B, urea and HbA1c. In the randomized trial, rosiglitazone significantly lowered MPO (p<0.01) and cLDL (p<0.05) whereas no changes were observed in the sulphonylurea group despite a similar reduction in HbA1c. The magnitude of reduction in plasma cLDL correlated with changes in MPO but not with HbA1c in the rosiglitazone group, suggesting that lowering MPO reduced plasma cLDL. Conclusions: Plasma cLDL is increased in patients with type 2 diabetes even in the absence of renal impairment and carbamylation of LDL in these subjects is mainly mediated by MPO and not by urea.
    Clinical Science 08/2013; · 4.86 Impact Factor


Available from